GLP-1 Beyond Weight Loss: Heart, Kidney, Liver, and Brain Research
An evidence-based review of GLP-1 receptor agonist research beyond diabetes and obesity. Covers cardiovascular protection (SELECT 20% MACE reduction, LEADER, SUSTAIN-6), heart failure with preserved ejection fraction (SUMMIT trial, GLP dual agonist peptide 38% risk reduction), renal protection (FLOW trial, 24% kidney composite risk reduction, FDA CKD approval), metabolic liver disease (MASH FDA approval for GLP-1 agonist peptide, 63% resolution at 72 weeks), neurodegeneration (Alzheimer's and Parkinson's preclinical data, 48% dementia risk reduction in cohort studies, exenatide-PD3 Phase 3 outcome), addiction and substance use disorders, and the emerging multi-organ therapeutic paradigm.